Below are the most recent publications written about "Remission Induction" by people in Profiles.
-
Alarcon Tomas A, Fein JA, Fried S, Flynn JR, Devlin SM, Fingrut WB, Anagnostou T, Alperovich A, Shah N, Fraint E, Lin RJ, Scordo M, Batlevi CL, Besser MJ, Dahi PB, Danylesko I, Giralt S, Imber BS, Jacoby E, Kedmi M, Nagler A, Palomba ML, Roshal M, Salles GA, Sauter C, Shem-Tov N, Shimoni A, Yahalom J, Yerushalmi R, Shah GL, Avigdor A, Perales MA, Shouval R. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma. Leukemia. 2023 01; 37(1):154-163.
-
Angus-Leppan H, Sperling MR, Villanueva V. Antiseizure medications (antiepileptic drugs) in adults: starting, monitoring and stopping. J Neurol. 2023 Jan; 270(1):573-581.
-
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME, Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022 07 12; 328(2):151-161.
-
Varanese M, Lauro A, Lattina I, Tripodi D, Daralioti T, Khouzam S, Marino IR, Stigliano V, D'Andrea V, Frattaroli S, Sorrenti S. Duodenal Follicular Lymphoma: Track or Treat? Dig Dis Sci. 2022 05; 67(5):1733-1738.
-
Pollard JA, Alonzo TA, Gerbing R, Brown P, Fox E, Choi J, Fisher B, Hirsch B, Kahwash S, Getz K, Levine J, Brodersen LE, Loken MR, Raimondi S, Tarlock K, Wood A, Sung L, Kolb EA, Gamis A, Meshinchi S, Aplenc R. Sorafenib in Combination With Standard Chemotherapy for Children With High Allelic Ratio FLT3/ITD+ Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML1031. J Clin Oncol. 2022 06 20; 40(18):2023-2035.
-
Getz KD, Alonzo TA, Sung L, Meshinchi S, Gerbing RB, Raimondi S, Hirsch B, Loken M, Brodersen LE, Kahwash S, Choi J, Kolb EA, Gamis A, Aplenc R. Cytarabine dose reduction in patients with low-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2022 01; 69(1):e29313.
-
O'Brien MM, Alonzo TA, Cooper TM, Levine JE, Brown PA, Slone T, August KJ, Benettaib B, Biserna N, Poon J, Patturajan M, Chen N, Simcock M, Zimmerman L, Kolb EA. Results of a phase 2, multicenter, single-arm, open-label study of lenalidomide in pediatric patients with relapsed or refractory acute myeloid leukemia. Pediatr Blood Cancer. 2021 07; 68(7):e28946.
-
Germans SK, Kulak O, Koduru P, Oliver D, Gagan J, Patel P, Anderson LD, Fuda FS, Chen W, Jaso JM. Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma-A Unique Entity. Am J Clin Pathol. 2020 11 04; 154(6):816-827.
-
Parisio K, Mangum DS, Powell J. A novel and successful therapeutic approach in the treatment of a patient with simultaneous relapsed Ewing sarcoma and therapy-related acute myeloid leukemia. Pediatr Blood Cancer. 2020 07; 67(7):e28240.
-
Abuelgasim KA, Alherz N, Alhejazi A, Damlaj M. Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports?and a?review of the literature. J Med Case Rep. 2020 Apr 23; 14(1):54.